



ASX ANNOUNCEMENT

23 March 2022

Completion of retail component of Entitlement Offer

On 21 February 2022, Chimeric Therapeutics Limited (ASX:CHM) (**Chimeric** or **Company**) announced the details of an accelerated non-renounceable entitlement offer (**Entitlement Offer**) to raise approximately \$18 million (before costs of the offer).

Chimeric announced the successful completion of the Institutional component of the Entitlement Offer on 23 February 2022, which raised approximately \$7.4 million, and the Retail Entitlement Offer closed on 18 March 2022, raising approximately \$4.3 million, bringing the total raise for the Entitlement Offer to \$11.7 million.

Approximately 25,385,228 fully paid ordinary shares (**New Shares**) at \$0.17 per share (**Offer Price**) together with approximately 25,385,228 attaching options exercisable at \$0.255 expiring 31 March 2024 (**New Options**) will be issued to successful applicants under the Retail Entitlement Offer.

New Options to be issued under the Entitlement Offer will be allotted on 25 March 2022, and can be exercised by completing and returning a personalised Option Exercise Form that will be issued to option holders on 28 March 2022.

Eligible retail shareholders who took up their full entitlement under the Retail Entitlement Offer (**Entitlement**) were also eligible to participate in a top-up facility by applying for additional Chimeric shares in excess of their Entitlement at the Offer Price.

Executive Chairman, Paul Hopper commented “In light of the current geo-political situation and challenging equity market conditions impacting the biotechnology sector, this capital raising result represents a strong outcome for the Company. I would like to thank our shareholders for their ongoing support.”

In consultation with Bell Potter Securities Ltd, the lead manager to the Offer, the Company is seeking to place the shortfall.

For personal use only



Indicative timetable¹

Remaining dates under the indicative timetable are set out below.

Event	Date
Allotment of New Shares and New Options issued under the Retail Entitlement Offer	25 March 2022
Allotment of New Options under the Institutional Entitlement Offer	25 March 2022
Despatch of holding statements for New Shares and New Options issued under the Retail Entitlement Offer, and New Options issued under the Institutional Entitlement Offer	28 March 2022
Normal ASX trading for New Shares and New Options issued under the Retail Entitlement Offer, and New Options under the Institutional Entitlement Offer, commences	28 March 2022

Electronic access

The prospectus (**Prospectus**) under which the Entitlement Offer was made is available at www.chimerictherapeutics.com.

For further information, please contact:

If you have questions about the Entitlement Offer, please contact the share registry, Boardroom Pty Ltd on 1300 737 760 (inside Australia) or +61 2 9290 9600 (outside Australia).

This announcement has been authorised by the Board of Chimeric.

Phillip Hains
Company Secretary

Important information

This document must not be distributed or released in the United States.

¹ All dates are indicative only and subject to change. Chimeric reserves the right to withdraw or vary the timetable without notice.

For personal use only